IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia. It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.